In recent years, the development of monoclonal antibodies targeting the neonatal Fc receptor (FcRn) has emerged as a promising and effective therapeutic option for the treatment of autoimmune diseases, including MG [4, 9]. The gene discussed is FCGRT; the disease is myasthenia gravis.